Öztürk H, Karapolat İ. Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer. World J Clin Cases 2023; 11(36): 8447-8457 [PMID: 38188218 DOI: 10.12998/wjcc.v11.i36.8447]
Corresponding Author of This Article
Hakan Öztürk, MD, Adjunct Associate Professor, Associate Professor, Department of Urology, Izmir University of Economics, 1825 sok no 12 Medicalpoint Hospital, Karsiyaka Izmir 35330, Turkey. drhakanozturk@yahoo.com.tr
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Dec 26, 2023; 11(36): 8447-8457 Published online Dec 26, 2023. doi: 10.12998/wjcc.v11.i36.8447
Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer
Hakan Öztürk, İnanç Karapolat
Hakan Öztürk, Department of Urology, Izmir University of Economics, Karsiyaka Izmir 35330, Turkey
İnanç Karapolat, Department of Nuclear Medicine, School of Medicine, İzmir Tınaztepe University, Izmir 35000, Turkey
Author contributions: Öztürk H participated in the design of the study and performed the statistical analysis; Karapolat İ carried out the nuclear medicine studies; Öztürk H and Karapolat İ drafted the manuscript; Öztürk H conceived the study, and participated in its design and coordination; all authors read and approved the final manuscript.
Institutional review board statement: There is no need approval. The research method is data analysis.
Informed consent statement: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. Additional information consent was obtained from all patients for which identifying information is included in this article.
Conflict-of-interest statement: All the authors declare that they have no competing interests. Financial support has not been received.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hakan Öztürk, MD, Adjunct Associate Professor, Associate Professor, Department of Urology, Izmir University of Economics, 1825 sok no 12 Medicalpoint Hospital, Karsiyaka Izmir 35330, Turkey. drhakanozturk@yahoo.com.tr
Received: September 22, 2023 Peer-review started: September 22, 2023 First decision: November 9, 2023 Revised: November 10, 2023 Accepted: December 6, 2023 Article in press: December 6, 2023 Published online: December 26, 2023
Abstract
BACKGROUND
The purpose of the present study was to examine retrospectively the contribution of 18Fluorodeoxyglucose positron emission tomography computed tomography (18FDG-PET/CT) to the evaluation of response to first-line gemcitabine plus cisplatin-based chemotherapy in patients with metastatic bladder cancer.
AIM
To evaluate the response to Gemcitabine plus Cisplatin -based chemotherapy using 18FDG-PET/CT imaging in patients with metastatic bladder cancer.
METHODS
Between July 2007 and April 2019, 79 patients underwent 18FDG-PET/CT imaging with the diagnosis of Metastatic Bladder Carcinoma (M-BCa). A total of 42 patients (38 male, 4 female) were included in the study, and all had been administered Gemcitabine plus Cisplatin-based chemotherapy. After completion of the therapy, the patients underwent a repeat 18FDG-PET/CT scan and the results were compared with the PET/CT findings before chemotherapy according to European Organisation for the Research and treatment of cancer criteria. Mean age was 66.1 years and standard deviation was 10.7 years (range: 41–84 years).
RESULTS
Of the patients, seven (16.6%) were in complete remission, 17 (40.5%) were in partial remission, six (14.3%) had a stable disease, and 12 (28.6%) had a progressive disease. The overall response rate was 57.1 percent.
CONCLUSION
18FDG-PET/CT can be considered as a successful imaging tool in evaluating response to first-line chemotherapy for metastatic bladder cancer. Anatomical and functional data obtained from PET/CT scans may be useful in the planning of secondline and thirdline chemotherapy.
Core Tip:18Fluorodeoxyglucose positron emission tomography computed tomography can be considered as a successful imaging tool in evaluating response to first-line chemotherapy for metastatic bladder cancer. Anatomical and functional data obtained from positron emission tomography computed tomography scans can be useful in the planning of second and third-line chemotherapy.
